Ramon Cacabelos

Summary

Affiliation: EuroEspes Biomedical Research Center
Country: Spain

Publications

  1. ncbi request reprint Pharmacogenomics in Alzheimer's disease
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders, 15166 Bergondo, La Coruna, Spain
    Mini Rev Med Chem 2:59-84. 2002
  2. ncbi request reprint Cerebrovascular risk factors in Alzheimer's disease: brain hemodynamics and pharmacogenomic implications
    Ramon Cacabelos
    Department of Clinical Neuroscience, EBIOTEC, EuroEspes Biomedical Research Center, Institute for CNS Disorders, Bergondo, Coruna, Spain
    Neurol Res 25:567-80. 2003
  3. ncbi request reprint Phenotypic profiles and functional genomics in Alzheimer's disease and in dementia with a vascular component
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders, EuroEspes Biotechnology EBIOTEC, Coruna, Spain and Department of Biotechnology and Genomics, Camilo José Cela University, Madrid, Spain
    Neurol Res 26:459-80. 2004
  4. ncbi request reprint Pharmacogenomics for the treatment of dementia
    Ramon Cacabelos
    From the EuroEspes Biomedical Research Center, Institute for CNS Disorders, Bergondo, La Coruna, Spain
    Ann Med 34:357-79. 2002
  5. ncbi request reprint Genomics and phenotypic profiles in dementia: implications for pharmacological treatment
    R Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders, EuroEspes Biotechnology EBIOTEC, Coruna, Spain
    Methods Find Exp Clin Pharmacol 26:421-44. 2004
  6. ncbi request reprint Genomic characterization of Alzheimer's disease and genotype-related phenotypic analysis of biological markers in dementia
    Ramon Cacabelos
    EuroEspes Chair of Biotechnology and Genomics, Camilo José Cela University, Madrid, Spain
    Pharmacogenomics 5:1049-105. 2004
  7. ncbi request reprint A pharmacogenomic approach to Alzheimer's disease
    R Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders, La Coruna, Spain
    Acta Neurol Scand Suppl 176:12-9. 2000
  8. ncbi request reprint The application of functional genomics to Alzheimer's disease
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders, 15166 Bergondo, Coruna, Spain
    Pharmacogenomics 4:597-621. 2003
  9. doi request reprint Pharmacogenomics in Alzheimer's disease
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders, Bergondo, Coruna, Spain
    Methods Mol Biol 448:213-357. 2008
  10. doi request reprint Pharmacogenomics and therapeutic prospects in dementia
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders, 15166 Bergondo, Coruna, Spain
    Eur Arch Psychiatry Clin Neurosci 258:28-47. 2008

Collaborators

  • Masatoshi Takeda
  • Ryouhei Ishii
  • Jerzy Leszek
  • Y Kubota
  • Ryota Hashimoto
  • L Corzo
  • J J Miguel-Hidalgo
  • José I Lao
  • Esteban Martinez
  • A Alvarez
  • X A Alvarez
  • V R M Lombardi
  • L Fernandez-Novoa
  • X Anton Alvarez
  • V R Lombardi
  • M Laredo
  • Lucia Fernandez-Novoa
  • Leonides Canuet
  • Iván Tellado
  • C Sampedro
  • Verónica Couceiro
  • I Etcheverria
  • H Moessler
  • R Zas
  • Jesus Figueroa
  • Carolina Sampedro
  • Herbert Moessler
  • Valter R M Lombardi
  • M Windisch
  • Carmen Fraile
  • D Corzo
  • P Perez
  • V Pichel
  • R Chacon
  • Dafin Muresanu
  • Manuel García-Fantini
  • R Lozano
  • Andres Gonzalez
  • M Garcia
  • C Linares
  • M Vargas
  • M Varela
  • E Granizo
  • M Aleixandre
  • D Muresanu
  • V Couceiro
  • T H Crook
  • S Seoane
  • Manfred Windisch
  • Dulce Arias
  • Valter Lombardi
  • Ignacio Etcheverría
  • Miguel Varela
  • Marta Laredo
  • Paula Pérez
  • Manuel Aleixandre
  • Raquel Zas
  • Angeles Hernandez
  • Victor Pichel
  • J Diaz
  • J M Sempere
  • J J Secades
  • R Mouzo
  • M Alcaraz

Detail Information

Publications44

  1. ncbi request reprint Pharmacogenomics in Alzheimer's disease
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders, 15166 Bergondo, La Coruna, Spain
    Mini Rev Med Chem 2:59-84. 2002
    ..Furthermore, the pharmacogenomics of AD may contribute in the future to optimise drug development and therapeutics, increasing efficacy and safety, and reducing side-effects and unnecessary costs...
  2. ncbi request reprint Cerebrovascular risk factors in Alzheimer's disease: brain hemodynamics and pharmacogenomic implications
    Ramon Cacabelos
    Department of Clinical Neuroscience, EBIOTEC, EuroEspes Biomedical Research Center, Institute for CNS Disorders, Bergondo, Coruna, Spain
    Neurol Res 25:567-80. 2003
    ..In this regard, cerebrovascular dysfunction should be considered a potential therapeutic target in dementia...
  3. ncbi request reprint Phenotypic profiles and functional genomics in Alzheimer's disease and in dementia with a vascular component
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders, EuroEspes Biotechnology EBIOTEC, Coruna, Spain and Department of Biotechnology and Genomics, Camilo José Cela University, Madrid, Spain
    Neurol Res 26:459-80. 2004
    ....
  4. ncbi request reprint Pharmacogenomics for the treatment of dementia
    Ramon Cacabelos
    From the EuroEspes Biomedical Research Center, Institute for CNS Disorders, Bergondo, La Coruna, Spain
    Ann Med 34:357-79. 2002
    ..The pharmacogenomics of AD may contribute in the future to optimise drug development and therapeutics, increasing efficacy and safety, and reducing side-effects and unnecessary costs...
  5. ncbi request reprint Genomics and phenotypic profiles in dementia: implications for pharmacological treatment
    R Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders, EuroEspes Biotechnology EBIOTEC, Coruna, Spain
    Methods Find Exp Clin Pharmacol 26:421-44. 2004
    ....
  6. ncbi request reprint Genomic characterization of Alzheimer's disease and genotype-related phenotypic analysis of biological markers in dementia
    Ramon Cacabelos
    EuroEspes Chair of Biotechnology and Genomics, Camilo José Cela University, Madrid, Spain
    Pharmacogenomics 5:1049-105. 2004
    ..All these genotypic and phenotypic variations bring about important consequences for the pharmacogenomics of AD...
  7. ncbi request reprint A pharmacogenomic approach to Alzheimer's disease
    R Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders, La Coruna, Spain
    Acta Neurol Scand Suppl 176:12-9. 2000
    ..All these data suggest that the therapeutic outcome in AD exhibits a genotype-specific pattern, and that a pharmacogenomic approach to AD might be a valuable strategy for drug development and monitoring...
  8. ncbi request reprint The application of functional genomics to Alzheimer's disease
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders, 15166 Bergondo, Coruna, Spain
    Pharmacogenomics 4:597-621. 2003
    ..Consequently, the understanding of functional genomics in AD will foster productive pharmacogenomic studies in the search for effective medications and preventive strategies in AD...
  9. doi request reprint Pharmacogenomics in Alzheimer's disease
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders, Bergondo, Coruna, Spain
    Methods Mol Biol 448:213-357. 2008
    ..The incorporation of pharmacogenetic/pharmacogenomic protocols to AD research and clinical practice can foster therapeutics optimization by helping to develop cost-effective pharmaceuticals and improving drug efficacy and safety...
  10. doi request reprint Pharmacogenomics and therapeutic prospects in dementia
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders, 15166 Bergondo, Coruna, Spain
    Eur Arch Psychiatry Clin Neurosci 258:28-47. 2008
    ....
  11. pmc Resting-state network disruption and APOE genotype in Alzheimer's disease: a lagged functional connectivity study
    Leonides Canuet
    EuroEspes Biomedical Research Center, Institute for CNS Disorders and Genomic Medicine, Corunna, Spain
    PLoS ONE 7:e46289. 2012
    ..This study aimed at identifying spatial patterns and effects of APOE genotype on resting-state oscillations and functional connectivity in patients with AD, using a physiological connectivity index called "lagged phase synchronization"...
  12. ncbi request reprint Molecular genetics of Alzheimer's disease and aging
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders, Bergondo, La Coruna, Spain
    Methods Find Exp Clin Pharmacol 27:1-573. 2005
    ..Furthermore, the pharmacogenomics of Alzheimer's disease may contribute in the future to optimize drug development and therapeutics, increasing efficacy and safety, and reducing side-effects and unnecessary costs...
  13. doi request reprint Reductions in qEEG slowing over 1 year and after treatment with Cerebrolysin in patients with moderate-severe traumatic brain injury
    X Anton Alvarez
    Department of Neuropharmacology, EuroEspes Biomedical Research Center, Santa Marta de Babío, Bergondo, A Coruna, Spain
    J Neural Transm 115:683-92. 2008
    ..Results of this exploratory study suggest that Cere might improve the functional recovery after brain injury and encourage the conduction of further controlled clinical trials...
  14. ncbi request reprint Genomics and pharmacogenomics of brain disorders
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders and Genomic Medicine, EuroEspes Chair of Biotechnology and Genomics, Camilo José Cela University, Bergondo, Corunna, Spain
    Curr Pharm Biotechnol 13:674-725. 2012
    ..The incorporation of genomic medicine procedures and pharmacogenomics into clinical practice, together with educational programs for the correct use of medication, must help to optimize therapeutics in CNS disorders...
  15. ncbi request reprint Decreased levels of serum nitric oxide in different forms of dementia
    Lola Corzo
    Department of Clinical Biochemistry, EuroEspes Biomedical Research Center, Santa Marta de Babío s n, 15166 Bergondo, La Coruna, Spain
    Neurosci Lett 420:263-7. 2007
    ..Our data suggest that NOx may contribute to the pathogenesis of dementia through a process mediated by HDL-cholesterol...
  16. ncbi request reprint Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders, Bergondo, Coruna, Spain
    Methods Find Exp Clin Pharmacol 29:1-91. 2007
    ..The incorporation of pharmacogenetic/pharmacogenomic protocols to AD research and clinical practice can foster therapeutics optimization by helping to develop cost-effective pharmaceuticals and improving drug efficacy and safety...
  17. ncbi request reprint Genetic variation and pharmacogenomics in Alzheimer disease
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders, Spain
    Seishin Shinkeigaku Zasshi 105:47-67. 2003
  18. doi request reprint Pharmacogenomics and therapeutic strategies for dementia
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders and Genomic Medicine, 15165 Bergondo, Coruna, Spain
    Expert Rev Mol Diagn 9:567-611. 2009
    ....
  19. ncbi request reprint Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion
    X A Alvarez
    EuroEspes Biomedical Research Center, A Coruna, Barcelona, Spain
    Methods Find Exp Clin Pharmacol 21:633-44. 1999
    ....
  20. ncbi request reprint Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogenetics
    Ramon Cacabelos
    Institute for CNS Disorders, EuroEspes Biomedical Research Center, EuroEspes Chair of Biotechnology and Genomics, Camilo José Cela University, Bergondo, Coruna, Spain
    Curr Alzheimer Res 4:479-500. 2007
    ..From these data, it can be postulated that pharmacogenetic and pharmacogenomic factors are responsible for 75-85% of the therapeutic response in AD patients treated with conventional drugs...
  21. doi request reprint Genomics and pharmacogenomics of schizophrenia
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, 15165 Bergondo, Coruna, Spain
    CNS Neurosci Ther 17:541-65. 2011
    ..Consequently, the incorporation of pharmacogenomic procedures both to drugs in development and drugs on the market would help to optimize therapeutics in SCZ and other central nervous system (CNS) disorders...
  22. pmc Genomics of Dementia: APOE- and CYP2D6-Related Pharmacogenetics
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders and Genomic Medicine, EuroEspes Chair of Biotechnology and Genomics, Camilo José Cela University, 15165 Bergondo, Spain
    Int J Alzheimers Dis 2012:518901. 2012
    ..APOE and CYP2D6 may cooperate, as pleiotropic genes, in the metabolism of drugs and hepatic function. The introduction of pharmacogenetic procedures into AD pharmacological treatment may help to optimize therapeutics...
  23. doi request reprint Influence of pharmacogenetic factors on Alzheimer's disease therapeutics
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders, Bergondo, Spain
    Neurodegener Dis 5:176-8. 2008
    ..The incorporation of pharmacogenetic protocols into AD research and clinical practice can foster therapeutics optimization by improving drug efficacy and safety...
  24. ncbi request reprint Pharmacogenetic basis for therapeutic optimization in Alzheimer's disease
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders, Bergondo, Coruna, Spain
    Mol Diagn Ther 11:385-405. 2007
    ....
  25. doi request reprint Pharmacogenomic protocols in CNS disorders and dementia
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders and Genomic Medicine, EuroEspes Chair of Biotechnology and Genomics, Camilo José Cela University, Bergondo, Coruna, Spain
    Neurodegener Dis 7:167-9. 2010
    ....
  26. doi request reprint Genomics and pharmacogenomics of dementia
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders and Genomic Medicine, Bergondo, Coruna, Spain
    CNS Neurosci Ther 17:566-76. 2011
    ....
  27. ncbi request reprint Double-blind, randomized, placebo-controlled pilot study with anapsos in senile dementia: effects on cognition, brain bioelectrical activity and cerebral hemodynamics
    X A Alvarez
    EuroEspes Biomedical Research Center, A Coruna, Spain
    Methods Find Exp Clin Pharmacol 22:585-94. 2000
    ..These effects of anapsos were more marked in demented patients with mild mental deterioration and/or with dementia of the Alzheimer type...
  28. ncbi request reprint Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease
    Antón Alvarez
    EuroEspes Biomedical Research Center, 15166 A Coruña, Spain
    Neurobiol Aging 28:533-6. 2007
    ..In addition, the combined determination of TNF-alpha and IGF-I might be useful to monitor anti-inflammatory and/or neurotrophic drug effects in AD...
  29. doi request reprint Pharmacogenomics of antipsychotics efficacy for schizophrenia
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders and Genomic Medicine, Bergondo, Coruna, Spain
    Psychiatry Clin Neurosci 65:3-19. 2011
    ....
  30. ncbi request reprint A novel mutation in the predicted TM2 domain of the presenilin 2 gene in a Spanish patient with late-onset Alzheimer's disease
    J I Lao
    Department of Clinical and Molecular Genetics, Basic and Clinical Neurosciences Research Center, EuroEspes Biomedical Research Center, A Coruna, Spain
    Neurogenetics 1:293-6. 1998
    ..In summary, we report here the first mutation in a presenilin gene in a Spanish AD case, which is the third mutation detected for the PS-2 gene...
  31. ncbi request reprint Microglial activation induced by factor(s) contained in sera from Alzheimer-related ApoE genotypes
    V R Lombardi
    EuroEspes Biomedical Research Center, Division of Biotechnology, Santa Marta de Babío, La Coruna, Spain
    J Neurosci Res 54:539-53. 1998
    ..These results strongly suggest that primary in vitro microglial cell cultures can be used as a screening model to test human sera as well as the effect of new potential drugs aimed at down-regulating microglia activation...
  32. ncbi request reprint Association between APOE epsilon4 allele and increased expression of CD95 on T cells from patients with Alzheimer's disease
    V R M Lombardi
    EBIOTEC, Biotechnology Division, La Coruna, Spain
    Methods Find Exp Clin Pharmacol 26:523-9. 2004
    ..Hyperexpression of Fas mRNA and surface Fas receptor on CD45RO(+) T lymphocytes may explain the occurrence of inflammatory cellular infiltrates in the CNS of AD patients...
  33. ncbi request reprint Pharmacogenomics and therapeutic prospects in Alzheimer's disease
    Ramon Cacabelos
    EuroEspes Biomedical Research Center, Institute for CNS Disorders, 15166 Bergondo, Coruna, Spain
    Expert Opin Pharmacother 6:1967-87. 2005
    ....
  34. ncbi request reprint In vitro regulation of rat derived microglia
    Valter R M Lombardi
    Ebiotec Biotechnology Division, La Coruna, Spain
    Neurotox Res 5:201-12. 2003
    ..These findings suggest that resting ramified microglial cells with neurotrophic activity can be induced with the combination of BME medium and small amounts of extracellular matrix growth promoters...
  35. ncbi request reprint Positive effects of cerebrolysin on electroencephalogram slowing, cognition and clinical outcome in patients with postacute traumatic brain injury: an exploratory study
    X Anton Alvarez
    EuroEspes Biomedical Research Center, Santa Marta de Babia, 15166 Bergondo, A Coruna, Spain
    Int Clin Psychopharmacol 18:271-8. 2003
    ..These promising preliminary results suggest that Cerebrolysin might be a useful treatment to improve the recovery of patients with traumatic brain damage, and encourage the conduction of confirmatory clinical trials...
  36. ncbi request reprint 19/20 kDa low molecular weight serum protein pattern: a novel potential biochemical prognostic marker for different types of dementia
    V R Lombardi
    Department of Biotechnology, EuroEspes, Biomedical Research Center, La Coruna, Spain
    Neurosci Lett 260:61-4. 1999
    ..The findings suggest that two proteins of 19 and 20kDa molecular weight, respectively, might be associated with disease progression in different types of dementia...
  37. ncbi request reprint Plasticity of Congo red staining displayed by subpopulations of neurons within the rat central nervous system
    J J Miguel-Hidalgo
    Department of Basic Neuroscience, EuroEspes Biomedical Research Center, Santa Marta de Babío, E 15166 Bergondo, La Coruna, Spain
    Cell Tissue Res 293:75-86. 1998
    ..Therefore, it is proposed that neurons labelled with the present Congo red technique might be in a reversible degenerative state or represent a particular physiological state in some areas of the central nervous system...
  38. ncbi request reprint Citicoline protects hippocampal neurons against apoptosis induced by brain beta-amyloid deposits plus cerebral hypoperfusion in rats
    X A Alvarez
    EuroEspes Biomedical Research Center, A Coruna, Spain
    Methods Find Exp Clin Pharmacol 21:535-40. 1999
    ..01 vs. CDP0) in a dose-related manner. Based on these results, it was concluded that citicoline exerts antiapoptotic, neuroprotective and antiamnesic effects in conditions of neurodegeneration induced by A beta 4 plus hypoperfusion...
  39. ncbi request reprint Neuropeptide dietary supplement N-PEP-12 enhances cognitive function and activates brain bioelectrical activity in healthy elderly subjects
    X A Alvarez
    Department of Neuropharmacology, EuroEspes Biomedical Research Center, Santa Marta de Babío, Bergonodo, A Coruna, Spain
    Methods Find Exp Clin Pharmacol 27:483-7. 2005
    ..Taken together, these data suggest that N-PEP-12 might be a reliable dietary supplement to be investigated for improving and, perhaps, maintaining brain function among healthy older adults...
  40. ncbi request reprint Histamine function in brain disorders
    L Fernandez-Novoa
    Department of Neurobiology, Institute for CNS Disorders, EuroEspes Biomedical Research Center, Bergondo 15166, La Coruna, Spain
    Behav Brain Res 124:213-33. 2001
    ..Peripheral cellular studies in health and disease, molecular studies on receptors and in vivo pharmacological studies may help us to better understand the function of the histaminergic system in health and disease...
  41. ncbi request reprint Effects of Cerebrolysin on in vitro primary microglial and astrocyte rat cell cultures
    V R Lombardi
    Biotechnology Division, EuroEspes, Basic and Clinical Neurosciences Research Center, La Coruna, Spain
    Methods Find Exp Clin Pharmacol 21:331-8. 1999
    ....
  42. ncbi request reprint Enhancement in immune function and growth using E-JUR-94013 supplementation
    V R M Lombardi
    EuroEspes Biotechnology, Santa Marta de Babío, La Coruna, Spain
    Methods Find Exp Clin Pharmacol 24:573-8. 2002
    ..Both effects resulted in better pig growth, demonstrating that E-JUR-94013 can also be used as a natural growth promoter and an immune enhancer...
  43. ncbi request reprint A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease
    X A Alvarez
    Euroespes Biomedical Research Centre, Santa Maria de Babio, Bergondo, La Coruna, Spain
    Eur J Neurol 13:43-54. 2006
    ..The percentage of patients reporting adverse events was similar across all study groups. Cere treatment was well tolerated and led to significant, dose-dependent improvement of cognition and global clinical impression...
  44. pmc Effects of FR-91 on immune cells from healthy individuals and from patients with non-Hodgkin lymphoma
    V R M Lombardi
    Departamento de Inmunología Celular, Euroespes Biotecnologia, La Coruna, 15166 Bergondo, Spain
    J Biomed Biotechnol 2009:187015. 2009
    ..In conclusion FR-91 seems to affect lymphocyte subpopulations, in vitro cytokine production, as well as mitogen-induced lymphocyte activation in a dose-dependent manner in both healthy individuals and NHL patients...